Art. -Nr.: HY-50934

Tacedinaline

(Synonyms: N-acetyldinaline; CI-994; Goe-5549)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.32%
CAS. Nr.: 112522-64-2
Formel: C₁₅H₁₅N₃O₂
Molecular Weight:269.30

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tacedinaline Chemical Structure

CAS. Nr.: 112522-64-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

IC₅₀ & Target^[1]

HDAC1

0.9 μM (IC₅₀)

HDAC2

0.9 μM (IC₅₀)

HD3

1.2 μM (IC₅₀)

HDAC1-3

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A-375	IC₅₀	11.3 μM Compound: Tacedinaline	Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay	[PMID: 30108928]
A-375	IC₅₀	9.64 μM Compound: 5; CI994	Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	10.17 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
A549	IC₅₀	15.96 μM Compound: CI-994	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	[PMID: 31223439]
A549	IC₅₀	16.45 μM Compound: 5; CI994	Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	20.1 μM Compound: 6; CI994	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
A549	IC₅₀	20.1 μM Compound: CI994	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	20.1 μM Compound: Tacedinaline	Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay	[PMID: 30108928]
Epithelial cell	IC₅₀	>50 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human mammary epithelial cells by MTT assay Cytotoxicity against human mammary epithelial cells by MTT assay	[PMID: 17941625]
HCT-116	EC₅₀	8.4 μM Compound: Cl-994	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay	[PMID: 35293758]
HCT-116	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HCT-116	IC₅₀	4 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17941625]
HCT-116	IC₅₀	6.39 μM Compound: 5; CI994	Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HCT-116	IC₅₀	7.71 μM Compound: 6; CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	9.83 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
HeLa	IC₅₀	1.81 μM Compound: 5; CI994	Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay	[PMID: 31103900]
HeLa	IC₅₀	1.81 μM Compound: CI994	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	13.43 μM Compound: 5; CI994	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HeLa	IC₅₀	18.02 μM Compound: CI994	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	18.78 μM Compound: CI994	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HepG2	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HepG2	IC₅₀	18.5 μM Compound: Tacedinaline	Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay	[PMID: 30108928]
HepG2	IC₅₀	18.51 μM Compound: 6; CI994	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HL-60	IC₅₀	2.8 μM Compound: CI994	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis	[PMID: 37948955]
JeKo-1	IC₅₀	1.9 μM Compound: CI994	Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis	[PMID: 37948955]
L02	IC₅₀	>100 μM Compound: CI994	Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis	[PMID: 37948955]
LNCaP	IC₅₀	7.4 μM Compound: 3, CI-994	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
MCF7	IC₅₀	13.16 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
MDA-MB-231	GI₅₀	0.17 μM Compound: 1	Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 18543902]
MDA-MB-231	IC₅₀	10.9 μM Compound: CI994	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis	[PMID: 37948955]
MGC-803	IC₅₀	11.6 μM Compound: 6; CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
MGC-803	IC₅₀	11.6 μM Compound: CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MM1.S	IC₅₀	4.7 μM Compound: CI994	Antiproliferative activity against human MM1.S cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis Antiproliferative activity against human MM1.S cells incubated for 48 hrs by resazurin dye based fluorescence micro plate reader analysis	[PMID: 37948955]
NCI-H1299	IC₅₀	33.79 μM Compound: CI994	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H1299	IC₅₀	33.8 μM Compound: Tacedinaline	Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H1299	IC₅₀	6.79 μM Compound: 2	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
NCI-H460	IC₅₀	9.7 μM Compound: Tacedinaline	Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H661	IC₅₀	20 μM Compound: CI-994	Antiproliferative activity against human NCI-H661 cells after 48 hrs Antiproliferative activity against human NCI-H661 cells after 48 hrs	[PMID: 18692397]
NIH3T3	IC₅₀	9.05 μM Compound: 5; CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
NIH3T3	IC₅₀	9.05 μM Compound: CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
PC-3	GI₅₀	0.29 μM Compound: 1	Growth inhibition of human PC3 cells after 5 days by MTT assay Growth inhibition of human PC3 cells after 5 days by MTT assay	[PMID: 18543902]
Sf9	IC₅₀	147 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass	[PMID: 30735902]
Sf9	IC₅₀	41 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence	[PMID: 30735902]
SMMC-7721	IC₅₀	>32 μM Compound: CI994	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SMMC-7721	IC₅₀	14.06 μM Compound: 5; CI994	Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
SMMC-7721	IC₅₀	16.9 μM Compound: Tacedinaline	Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay	[PMID: 30108928]

In Vitro

Tacedinaline (N-acetyldinaline) is a novel oral compound with a wide spectrum of antitumor activity in preclinical models. The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest. Tacedinaline (N-acetyldinaline) is combined with antineoplastic agents commonly used in non-small cell lung cancer cell line management, a marked synergism of action (R=1.8, R=1.5) is observed between Tacedinaline (N-acetyldinaline) (40 μM) and gemcitabine (0.01 μM) at 48 and 72 h of treatment^[2].
Tacedinaline (N-acetyldinaline) inhibits mitogen-stimulated blood lymphocyte proliferation with an IC₅₀ value of 3 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tacedinaline (CI-994) can effect lymphoid tissue in rats within 1 day of a single oral dose, that effects are generally reversible within 7 days^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 112522-64-2
Appearance Solid
Molecular Weight 269.30
Formel C₁₅H₁₅N₃O₂
Color White to gray
SMILES

O=C(NC1=C(N)C=CC=C1)C2=CC=C(NC(C)=O)C=C2
Synonyms

N-acetyldinaline; CI-994; Goe-5549
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All OthersRT-PCRWB

Sort by:

Journal Impact Factor

Nat Commun

YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. [Abstract]

2023 Sep 22;14(1):5916. PMID: 37739954

Tacedinaline purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 22;14(1):5916. [Abstract]

Tacedinaline (1 μM). Benzamide HDAC inhibitors induce YAP protein in H209 and H69 cells.
Nutrients

Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption. [Abstract]

2023 Jun 15;15(12):2760. PMID: 37375664

Tacedinaline purchased from MedChemExpress. Usage Cited in: Nutrients. 2023 Jun 15;15(12):2760. [Abstract]

Tacedinaline (2.5, 25, 250 μM), which inhibits HDACs from class I, decreased the cytokine-induced rise in FD4 permeability.
Int J Mol Sci

Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition. [Abstract]

2022 Apr 2;23(7):3980. PMID: 35409339

Tacedinaline purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Apr 2;23(7):3980. [Abstract]

Tacedinaline (10 μM). Effect of HDAC inhibitors on CXCL10 release.
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Front Neurosci

Dose Effects of Histone Deacetylase Inhibitor Tacedinaline (CI-994) on Antipsychotic Haloperidol-Induced Motor and Memory Side Effects in Aged Mice. [Abstract]

2021 Oct 6;15:674745. PMID: 34690667
SLAS Discov

A neuronal cell-based reporter system for monitoring the activity of HDAC2. [Abstract]

2022 Dec;27(8):440-447. PMID: 36240996

Tacedinaline purchased from MedChemExpress. Usage Cited in: SLAS Discov. 2022 Dec;27(8):440-447. [Abstract]

SH-SY5Y cells were treated with 3 μM or 10 μM CI-994 (Tacedinaline), or with an equal volume of DMSO for 24 hours, and then RNA was extracted and analyzed by RT-qPCR.
bioRxiv

2026 May 7.
Patent

US20250161243A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (185.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7133 mL

18.5667 mL

37.1333 mL

5 mM

0.7427 mL

3.7133 mL

7.4267 mL

10 mM

0.3713 mL

1.8567 mL

3.7133 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[4]

Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief]

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief]

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief]

[4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7133 mL	18.5667 mL	37.1333 mL	92.8333 mL
	5 mM	0.7427 mL	3.7133 mL	7.4267 mL	18.5667 mL
	10 mM	0.3713 mL	1.8567 mL	3.7133 mL	9.2833 mL
	15 mM	0.2476 mL	1.2378 mL	2.4756 mL	6.1889 mL
	20 mM	0.1857 mL	0.9283 mL	1.8567 mL	4.6417 mL
	25 mM	0.1485 mL	0.7427 mL	1.4853 mL	3.7133 mL
	30 mM	0.1238 mL	0.6189 mL	1.2378 mL	3.0944 mL
	40 mM	0.0928 mL	0.4642 mL	0.9283 mL	2.3208 mL
	50 mM	0.0743 mL	0.3713 mL	0.7427 mL	1.8567 mL
	60 mM	0.0619 mL	0.3094 mL	0.6189 mL	1.5472 mL
	80 mM	0.0464 mL	0.2321 mL	0.4642 mL	1.1604 mL
	100 mM	0.0371 mL	0.1857 mL	0.3713 mL	0.9283 mL

Keywords

Tacedinaline

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tacedinaline

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Human Metabolite Library

Osteogenesis Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Tacedinaline

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tacedinaline Related Classifications

Art. -Nr.: HY-50934